New antibody trial aims to ease core autism symptoms
NCT ID NCT06500637
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 study tests whether TB006, an antibody that targets a protein called Galectin-3, can improve core symptoms of autism in adults aged 18 to 35. Forty-five participants will be randomly assigned to receive either TB006 or a placebo for 14 weeks, with an open-label extension for those on placebo. The study measures changes in autism severity using clinician-rated scales and neurodevelopmental assessments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TB006 (a monoclonal antibody targeting Galectin-3)
What this could lead to
If successful, this could point toward a new treatment option for core autism symptoms in adults.
What could go wrong
This is an early Phase 2 trial with only 45 participants, so results may not apply broadly. The drug may not show significant benefit over placebo, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTISM SPECTRUM DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Rossignol Medical Center
RECRUITINGPhoenix, Arizona, 85050, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Rossignol Medical Center
RECRUITINGAliso Viejo, California, 92656, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••